Elan   2Q Revenues: $56.3 million ($0.2 million 2Q12) 2Q Earnings: $2.3 billion (loss of $28.5 million 2Q12) YTD Revenues: $56.5 million (n/a) YTD Earnings: $2.4 billion (loss of $60.3 million YTD12) Comments: Results included $2.5 billion income from the transfer of Tysabri to partner Biogen. Under the Tysabri transaction, Elan received an upfront payment of $3.3 billion and will continue to receive royalties on Tysabri in-market sales. Earnings in the quarter includes a net loss from conti...